Stock Market Reviews

Read and share opinions on BCDA (BioCardia, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results
  Nov 12, 2025
• BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
  Nov 10, 2025
• BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025
  Nov 6, 2025
• BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
  Oct 30, 2025
• BioCardia Inc. (BCDA): 2025 Product Pipeline and Strategy Analysis Report
  Oct 21, 2025
• BioCardia Regains Compliance with Nasdaq Listing Requirements
  Oct 2, 2025
• BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure
  Sep 22, 2025
• Bullish BioCardia Insider Buying Worth US$1.06m Yet To Pay Off
  Sep 20, 2025
• BioCardia Announces Pricing of Up To $12 Million Public Offering
  Sep 18, 2025
• BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up
  Sep 18, 2025
• BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025
  Sep 4, 2025
• BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D™ Fusion Imaging for Interventional Cardiology
  Aug 13, 2025
• BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results
  Aug 11, 2025
• BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025
  Aug 6, 2025
• BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter
  Aug 4, 2025
• BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP® Cell Therapy in Ischemic Heart Failure
  Jul 24, 2025
• Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction
  Jul 16, 2025
• BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System
  Jun 25, 2025
• BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025
  May 21, 2025
• BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ...
  May 15, 2025